FDA fast-tracks GSK’s chronic hep B therapy bepirovirsen

FDA fast-tracks GSK’s chronic hep B therapy bepirovirsen

Source: 
Pharmaphorum
snippet: 

GSK’s antisense-based drug for chronic hepatitis B (CHB), bepirovirsen, will get a rapid six-month review from the FDA when it is filed for approval, said the drugmaker this morning.